ReviewClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2020
Recent Advances in the Pharmacology of Tardive Dyskinesia.
Review in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers.Clinical and translational science · 2023Trial
- Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders.Schizophrenia (Heidelberg, Germany) · 2026Article
- Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesia.Schizophrenia bulletin · 2026Article
- Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment-Resistant Schizophrenia Patient.Case reports in psychiatry · 2026Article
- Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats.Molecular neurobiology · 2025Article
- Dopamine Toxicity Induces ROS-Dependent Death of Murine Neuroblastoma Cells: Impact on the Interactions of Cofilin With UCHL1 and MMP9.Neurochemical research · 2025Article
- Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.Neurotoxicity research · 2024Article
- Treatment of tardive dyskinesia with clonazepam: A case report.Clinical case reports · 2024Article
- Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.Journal of patient-reported outcomes · 2023Article
- Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications.Frontiers in psychiatry · 2023Article
- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.Advances in neurobiology · 2023Article
- Treatable Hyperkinetic Movement Disorders Not to Be Missed.Frontiers in neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine transporter-2 (VMAT2) inhibitors offers hope for reducing the impact of TD. Although these drugs represent a significant advance in patient care and a practical step forward in providing relief for patients with TD, understanding of the pharmacology of TD that could inform future research to prevent and reverse TD remains incomplete. This review surveys evidence for the effectiveness of VMAT2 inhibitors and other agents in the context of theories of pathogenesis of TD. In patients for whom VMAT2 inhibitors are ineffective or intolerable, as well as for extending therapeutic options and insights regarding underlying mechanisms, a review of clinical trial results examined as experimental tests of etiologic hypotheses is worthwhile. There are still compelling reasons for further investigations of the pharmacology of TD, which could generate alternative preventive and potentially curative treatments. Finally, benefits from novel drugs are best realized within an overall treatment strategy addressing the condition and needs of individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.